Health · 1 views
Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b…
AI Summary
Subcutaneous administration of tarlatamab was well tolerated in patients with previously treated extensive‑stage small cell lung cancer. The phase 1b DeLLphi‑308 study reported preliminary antitumor activity for the drug.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trialContinue reading
- Journalists Detail Data on Suicide, Primary Care Shortages, and Gun ViolenceContinue reading
- PET/MRI improves presurgical lesion detection in pediatric epilepsyContinue reading
- Rheumatoid arthritis: Timely diagnosis and early treatment initiation are key determinants of prognosisContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow